Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

Imai, Yumiko; Chikayama, Taku; Nakazawa, Masatoshi; Watanabe, Kazuhiro; Ando, Satsuki; Mizuno, Yoshinobu; Yoshino, Kiyoko; Sugawara, Kayoko; Hamaoka, Kazuhiro; Fujimori, Kenji; Inao, Mie; Nakayama, Nobuaki; Oka, Masashi; Nagoshi, Sumiko; Mochida, Satoshi

doi:10.1007/s00535-011-0475-x

Cited by 16 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with cirrhosis commonly have fine arterioportal shunts and hepatofugal blood flow (32). Anticancer drugs administered during TACE are thought to be washed out immediately, except for Miripla (33), but these drugs are likely to be carried in blood that flows outside subsegments or the entire liver, via the same hemodynamic route used in the dissemination of liver cancer cells. Anticancer drugs may suppress recurrence of micro-level dissemination of cells during TACE that cannot be detected at the macro level (34,35).…”

Section: Univariate Multivariate ------------------------------------mentioning

confidence: 99%

Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Percutaneous radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) is an effective, standard therapy against small hepatocellular carcinoma (HCC). However, there is debate regarding the effectiveness of RFA combined with TACE (RFA/TACE) compared with RFA alone. These two approaches were compared for the treatment of early HCC. The present study examined 83 HCC tumors in 83 patients treated with RFA between April 2007 and August 2014 at three medical institutions. All HCCs were single hypervascular tumors, with a median diameter of 16 mm (range, 6-30 mm). The overall survival (OS) rate of all patients (n=83) was 97.5% at 1 year, 82.8% at 3 years and 48.6% at 5 years, and the local recurrence rate of all patients was 14.3% at 1 year, 32.3% at 3 years and 36.5% at 5 years. The tumor-free survival (TFS) rate of all patients was 95.1% at 1 year, 56.3% at 3 years and 23.4% at 5 years. Compared with RFA alone, RFA/TACE significantly improved OS (P<0.001), intrahepatic distant recurrence (IDR; P=0.038) and TFS (P=0.010). A univariate analysis of prognostic indicators revealed that age <70 years (P=0.008), aspartate transaminase <40 IU/l (P=0.003), alanine aminotransferase <40 IU/l (P=0.006) and platelet count >10x10 4 /µl (P=0.05) were associated with a high survival rate. Multivariate analysis identified RFA/TACE [hazard ratio (HR), 0.108; P=0.001] as an independent prognostic indicator. RFA/TACE was identified as the only independent indicator of IDR (HR: 0.467; P=0.042) and TFS (HR: 0.452; P=0.012). RFA/TACE improved OS rate, IDR and TFS compared with RFA alone. The data suggested that RFA/TACE should be considered for the treatment of single hypervascular HCC.

show abstract

Section: Univariate Multivariate ------------------------------------mentioning

confidence: 99%

Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…MPT is theoretically a good candidate for this kind of agent [22,23], although no strong evidence is available. However, in actual clinical practice, many physicians have pointed out that MLS injection requires unusually high pressure, particularly through a microcatheter system, due to its high viscosity [24][25][26][27]. This results in lower local control compared with a lipiodol emulsion with conventional chemotherapeutic agents.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Hirakawa

Yamanouchi

Tsuruta

et al. 2017

Interventional Radiology

View full text Add to dashboard Cite

Purpose: This study aimed to retrospectively compare the local control and safety of microballoonoccluded transarterial chemoembolization (B-TACE) using miriplatin (MPT) and of conventional TACE (C-TACE) using epirubicin (EPIR) for hepatocellular carcinoma (HCC).Materials and Methods: Thirty-nine patients (24 men, 15 women; mean age, 73.4 years) were treated using B-TACE with MPT (MPT-B-TACE group). As a historical comparison, 23 patients (13 men, 10 women; mean age, 72.2 years) who were treated using C-TACE with EPIR (EPIR-C-TACE group) were investigated. The therapeutic effect within 2 weeks after treatment was compared between the groups based on the Response Evaluation Criteria in Cancer of the Liver (RECICL), and time to local recurrence was compared based on the Kaplan-Meier method and log-rank tests. The side effects were compared based on the Common Terminology Criteria for Adverse Events (ver. 4.0).Results: No significant differences were noted in patients' characteristics between the groups. The overall incidence of postembolization syndrome was significantly lower in the MPT-B-TACE group than in the EPIR-C-TACE group (p<0.05), but two cases in the MPT-B-TACE group developed grade 2 cholecystitis. Based on the RECICL, the objective response rate, including TE4 and TE3, within 2 weeks after treatment was significantly higher in the MPT-B-TACE group (89.7%) than in the EPIR-C-TACE group (78.3%). Overall, local recurrence was significantly less frequent in the MPT-B-TACE group than in the EPIR-C-TACE group (p=0.02).Conclusion: MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-C-TACE without a significant increase in adverse effects.

show abstract

“…We hypothesized that miriplatin-iodized oil suspension might help to expand ablative zone sizes and that platinum remains in both the ablative zone and the surrounding hyperemic rim to ensure an antitumor effect on HCC [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

“…Recently, hepatic arterial injection of miriplatin-iodized oil suspension has been used as a safe and useful treatment of HCC [13,14]. Miriplatin (Miripla; Dainippon Sumitomo Pharma, Osaka, Japan) is a platinum complex that accumulates and persists in the tumor after arterial injection.…”

Section: Introductionmentioning

confidence: 99%

Radiofrequency Ablation After Arterial Injection of Miriplatin–Iodized Oil Suspension Into Swine Liver: Ablative Zone Size and Tissue Platinum Concentration

Yamanaka

Takaki

Nakatsuka

et al. 2013

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

show abstract

Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

Abstract: Miriplatin is a useful and safe agent for TACE in patients with HCC stage I or II and/or JIS score 0 or 1 only when radiofrequency ablation and liver resection cannot be performed.

Cited by 16 publications

References 22 publications

Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma

Utility of percutaneous radiofrequency ablation alone or combined with transarterial chemoembolization for early hepatocellular carcinoma

Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

Radiofrequency Ablation After Arterial Injection of Miriplatin–Iodized Oil Suspension Into Swine Liver: Ablative Zone Size and Tissue Platinum Concentration

Contact Info

Product

Resources

About